PerkinElmer to Acquire BioLegend in $5.25-Billion Deal

PerkinElmer has entered into an agreement on July 26, 2021 to acquire BioLegend, a global developer and manufacturer of antibodies and reagents used in biomedical research (cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing). The transaction is expected to close by the end of 2021 and is valued at $5.25 billion.

With this acquisition, PerkinElmer will offer solutions in areas such as cell and gene therapy discovery. The company will also move into new spaces like proteogenomics. BioLegend’s new headquarters in San Diego, Calif. will serve as PerkinElmer’s center for research reagent content development.

Source: PerkinElmer